Retatrutide, a novel dual-acting glucose-responsive incretin mimetic, represents a significant leap in peptide therapeutics for the management of type 2 sugar disorders and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor activator and a GIP receptor agonist, offering a more